1. Home
  2. NVNI vs IFRX Comparison

NVNI vs IFRX Comparison

Compare NVNI & IFRX Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.

Logo Nvni Group Limited

NVNI

Nvni Group Limited

HOLD

Current Price

$1.28

Market Cap

12.9M

Sector

N/A

ML Signal

HOLD

Logo InflaRx N.V.

IFRX

InflaRx N.V.

HOLD

Current Price

$0.95

Market Cap

60.6M

Sector

Health Care

ML Signal

HOLD

Company Overview

Basic Information
Metric
NVNI
IFRX
Founded
2019
2007
Country
Brazil
Germany
Employees
618
N/A
Industry
Biotechnology: Pharmaceutical Preparations
Sector
Health Care
Exchange
Nasdaq
Nasdaq
Market Cap
12.9M
60.6M
IPO Year
N/A
2017

Fundamental Metrics

Financial Performance
Metric
NVNI
IFRX
Price
$1.28
$0.95
Analyst Decision
Strong Buy
Analyst Count
0
6
Target Price
N/A
$8.50
AVG Volume (30 Days)
85.1K
171.7K
Earning Date
01-01-0001
01-01-0001
Dividend Yield
N/A
N/A
EPS Growth
N/A
N/A
EPS
N/A
N/A
Revenue
N/A
N/A
Revenue This Year
$6.67
N/A
Revenue Next Year
$26.67
$1,054.36
P/E Ratio
N/A
N/A
Revenue Growth
N/A
N/A
52 Week Low
$0.14
$0.71
52 Week High
$4.94
$1.94

Technical Indicators

Market Signals
Indicator
NVNI
IFRX
Relative Strength Index (RSI) 36.29 52.69
Support Level $1.10 $0.75
Resistance Level $1.64 $1.16
Average True Range (ATR) 0.13 0.07
MACD 0.04 0.01
Stochastic Oscillator 39.54 50.85

Price Performance

Historical Comparison
NVNI
IFRX

About NVNI Nvni Group Limited

Nvni Group Ltd is a holding company that conducts all of its business through Nuvini SA and Nuvini acquired companies. Nuvini S.A. acquires and operates software companies within SaaS markets in Brazil. Nuvini S.A. is the private serial software business acquirer in Brazil and intends to use funding and capital markets access to continue expanding its acquisition plans in Brazil and Latin America. The Company has determined that it has a single operating and reportable segment which is multi-vertical SaaS solution model.

About IFRX InflaRx N.V.

InflaRx NV is a clinical-stage biopharmaceutical company focused on applying proprietary anti-C5a/C5aR technology to discover and develop first-in-class, potent, and specific inhibitors of the complement activation factor known as C5a and its receptor known as C5aR. C5a is an inflammatory mediator involved in the progression of a wide variety of autoimmune and other inflammatory diseases. Its product candidate, vilobelimab, is a novel intravenously delivered first-in-class anti-C5a monoclonal antibody that selectively binds to free C5a and has demonstrated disease-modifying clinical activity and tolerability in multiple clinical settings.

Share on Social Networks: